



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket Number	0036119.00200US3
-------	---	----	---	------------------------	------------------

Complete if Known

Application Number	41/283,288-Conf. #4075
Filing Date	November 18, 2005
First Named Inventor	Aranapakam M. Venkatesan
Art Unit	N/A
Examiner Name	Not Yet Assigned

10/693,915

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/MB/	AA*	US-20030080312-A1	08-10-2004	Seddon et al.	
	AB*	US-20040043978	03-01-2004	Venkatesan et al.	
	AC*	US-20050101654-A1	09-26-2006	Weiberth et al.	
	AD*	US-4,206,067	06-03-1980	MacKinnon	
	AE*	US-4,891,369	01-02-1990	Torii et al.	
	AF*	US-6,268,393	07-31-2001	Xu et al.	
	AG*	US-7,018,997-A1	03-28-2006	Venkatesan et al.	
/MB/	AH*	US-7,112,582-A1	09-26-2006	Venkatesan et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ -Number ⁴ -Kind Code ⁵ (if known)				
/MB/	BA	EP-0167050	01-08-1986	Beecham Group Plc		
/MB/	BB	WO-03/093277	11-13-2003	Wyeth Corp et al.		
/MB/	BC	WO-03/093279	11-13-2003	Wyeth Corp et al.		
/MB/	BD	WO-03/093280	11-13-2003	Wyeth Corp et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/MB/	CA	BUSH, "β-Lactamases of Increasing Clinical Importance", Cur. Pharm. Design, 5:839-845 (1999)	
	CB	BUSH, et al., "Kinetic Interactions of Tazobactam with β-Lactamases from All Major Structural Classes", Antimicrobial Agents and Chemotherapy, 37(4):851-858(1993)	
	CC	CIGNARELLA, et al., "6-Chloro- and 6-Bromopenicillanic Acids", J. Org. Chem., 27:2668-2669 (1962)	
	CD	COLEMAN, "Anti-Infectives: An Update on β-Lactamases and β-Lactamase Inhibitors", Expert Opin. Invest. Drugs, 4(8):693-704 (1995)	
	CE	Grant and Hackh's Chemical Dictionary, Fifth Edition, page 412 (1987)	
	CF	HASLAM, "Protection of Carboxyl Groups", Protective Groups in Organic Chemistry, Chapter 5, McOmie, ed., Plenum Press, pg. 183-215 (1973)	
	CG	JONES, "Resistance Patterns Among Nosocomial Pathogens: Trends Over the Past Few Years", Chest, 119:397S-404S (2001)	
/MB/	CH	OSBORNE, et al., "A Novel and Stereocontrolled Synthesis of (5R)-(Z)-6-(1-Methyl-1,2,3-Triazol-4-Ylmethylene)Penem-3-Carboxylic Acid, A Potent Broad Spectrum β-Lactamase	

Examiner Signature	/Mark Berch/ (04/23/2007)	Date Considered	
--------------------	---------------------------	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	11/288,288 Conf. #4075
				Filing Date	November 18, 2005
				First Named Inventor	Aranapakam M. Venkatesan
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	0036119.00200US3

10/693,315

		Inhibitor", Journal of The Chemical Society, Letchworth, Great Britain, 6:371-373 (1989)	
/MB/	CI	PAYNE, et al., "β-Lactamase Epidemiology and the Utility of Established and Novel β-Lactamase Inhibitors", Exp. Opin. Invest. Drugs, 9(2):247-261 (2000)	
/MB/	CJ	RIETSCHA, et al., "Collaborative Clinical Pharmacokinetics Service in a Community Hospital", Am. J. Hosp. Pharm., 41:463-477 (1984)	
/MB/	CK	SANDERS, "Cefepime: The Next Generation?", Clin. Infect. Dis., 17:369-379 (1993)	
/MB/	CL	SUTHERLAND, "β-Lactam/β-Lactamase Inhibitor Combinations: Development, Antibacterial Activity and Clinical Applications", Infection, 23(4):191-200 (1995)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Mark Berch/ (04/23/2007)	Date Considered	
--------------------	---------------------------	-----------------	--



PTO/SB/08A/B (09-08)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	0036119.00227US1/AM100905
-------	---	----	---	------------------------	---------------------------

Complete If Known

Application Number	10/693,315-Conf. #1495
Filing Date	October 24, 2003.
First Named Inventor	Takao Abe
Art Unit	1624
Examiner Name	M. L. Berch
Attorney Docket Number	0036119.00227US1/AM100905

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/MB/A*		US-20040053913	03-01-2004	Abe et al.	
/MB/AB*		US-20040077622-A1	09-26-2006	Venkatesan et al.	
/MB/AC*		US-20040132708	07-01-2004	Abe et al.	
/MB/AD*		US-5,911,985	06-15-1999	Coleman et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/MB/A		WO-91/12815	09-05-1991	Squibb Bristol Myers Co		
/MB/BB		EP-0 313 458 A2	04-26-1989	Roussel Uclaf		
/MB/BC		EP-0-313 458 B1	08-11-1993	Roussel Uclaf		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/MB/CA		WEISS, et al., "In Vitro and In Vivo Activities of Novel 6-Methylidene Penems as Bets-Lactamase Inhibitors", Antimicrobial Agents and Chemotherapy, 48(12):4589-4596 (2004)	
/MB/CB		Invitation to Pay Additional Fees and Partial Search Report dated March 9, 2007 for PCT/US2006/032781	
/MB/CC		Delphion Integrated View of EP0313458B1 dated March 29, 2007	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Mark Berch/ (04/23/2007)	Date Considered	
-----------------------	---------------------------	--------------------	--



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	11/200,200 Conf. #4076
Filing Date	November 18, 2005
First Named Inventor	Aranapakam M. Venkatesan
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	0036449-002000US3

10/69335
10/24/2003
Takao Abe
1624
Berch
36119.227US1
AM100905P1**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/MB/	AA*	US-20030080312-A1	08-10-2004	Seddon et al.	
	AB*	US-20040043978	03-01-2004	Venkatesan et al.	
	AC*	US-20050101654-A1	09-26-2006	Weiberth et al.	
	AD*	US-4,206,067	06-03-1980	MacKinnon	
	AE*	US-4,891,369	01-02-1990	Torii et al.	
	AF*	US-6,268,393	07-31-2001	Xu et al.	
	AG*	US-7,018,997-A1	03-28-2006	Venkatesan et al.	
/MB/	AH*	US-7,112,582-A1	09-26-2006	Venkatesan et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ -Number-Kind Code ⁴ (if known)				
/MB/	BA	EP-0167050	01-08-1986	Beecham Group Plc		
/MB/	BB	WO-03/093277	11-13-2003	Wyeth Corp et al.		
/MB/	BC	WO-03/093279	11-13-2003	Wyeth Corp et al.		
/MB/	BD	WO-03/093280	11-13-2003	Wyeth Corp et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/MB/	CA	BUSH, "β-Lactamases of Increasing Clinical Importance", Cur. Pharm. Design, 5:839-845 (1999)	
	CB	BUSH, et al., "Kinetic Interactions of Tazobactam with β-Lactamases from All Major Structural Classes", Antimicrobial Agents and Chemotherapy, 37(4):851-858(1993)	
	CC	CIGNARELLA, et al., "6-Chloro- and 6-Bromopenicillanic Acids", J. Org. Chem., 27:2668-2669 (1962)	
	CD	COLEMAN, "Anti-Infectives: An Update on β-Lactamases and β-Lactamase Inhibitors", Expert Opin. Invest. Drugs, 4(8):693-704 (1995)	
	CE	Grant and Hackh's Chemical Dictionary, Fifth Edition, page 412 (1987)	
	CF	HASLAM, "Protection of Carboxyl Groups", Protective Groups in Organic Chemistry, Chapter 5, McOmie, ed., Plenum Press, pp. 183-215 (1973)	
	CG	JONES, "Resistance Patterns Among Nosocomial Pathogens: Trends Over the Past Few Years", Chest, 119:397S-404S (2001)	
/MB/	CH	OSBORNE, et al., "A Novel and Stereocontrolled Synthesis of (5R)-(Z)-6-(1-Methyl-1,2,3-Triazol-4-Ylmethylene)Penem-3-Carboxylic Acid, A Potent Broad Spectrum β-Lactamase	

Examiner Signature	/Mark Berch/ (04/23/2007)	Date Considered	
-----------------------	---------------------------	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	11/283,288 Conf. #4075
				Filing Date	November 18, 2005
				First Named Inventor	Aranapakem M. Venkatesan
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	0036419-00200U63

10/693315
10/24/2003
Takao Abe
1624
Berch
36119.277US1
AM 100905P1

		Inhibitor", Journal of The Chemical Society, Letchworth, Great Britain, 6:371-373 (1989)	
/MB/	CI	PAYNE, et al., "β-Lactamase Epidemiology and the Utility of Established and Novel β-Lactamase Inhibitors", Exp. Opin. Invest. Drugs, 9(2):247-261 (2000)	
/MB/	CJ	RIETSCHA, et al., "Collaborative Clinical Pharmacokinetics Service in a Community Hospital", Am. J. Hosp. Pharm., 41:463-477 (1984)	
/MB/	CK	SANDERS, "Cefepime: The Next Generation?", Clin. Infect. Dis., 17:369-379 (1993)	
/MB/	CL	SUTHERLAND, "β-Lactam/β-Lactamase Inhibitor Combinations: Development, Antibacterial Activity and Clinical Applications", Infection, 23(4):191-200 (1995)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Mark Berch/ (04/23/2007)	Date Considered	
--------------------	---------------------------	-----------------	--